Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Rachel Midgley" Clear advanced filters

  • The use of adjuvant chemotherapy for stage III colorectal cancer is well established, but the use of this approach in patients with stage II colon cancer is more controversial. Midgley and Kerr highlight data from the QUASAR 1 trial, which provide compelling evidence for the use of adjuvant chemotherapy. The use of combination therapeutic options, the rationale for considering morphologic or molecular features to select and individualize therapy, and the crucial question of which patients would benefit most from adjuvant chemotherapy, are discussed.

    • Rachel Midgley
    • David J Kerr
    Reviews
    Nature Clinical Practice Oncology
    Volume: 2, P: 364-369

  • Capecitabine is commonly substituted for conventional 5-fluorouracil chemotherapy based on evidence of the efficacy equivalence of these two drugs and the lack of an increase in overall toxic effects when capecitabine is used. This Review summarizes why there may not be a universally applicable dose for capecitabine because of interpatient differences in basic physiology, pharmacogenomics and diet. The authors also discuss which of these factors contribute to the inter-regional geographical variation in capecitabine toxicity, and the reasons for modifying the starting dose.

    • Rachel Midgley
    • David J Kerr
    Reviews
    Nature Clinical Practice Oncology
    Volume: 6, P: 17-24

  • Doublet fluoropyrimidine-based chemotherapy is the standard of care for the first-line treatment of metastatic colorectal cancer (mCRC). However, single fluoropyrimidine-based therapy remains an important alternative. In this article, we highlight the potential impact of a recent trial assessing the addition of bevacizumab to capecitabine in the first-line treatment of mCRC.

    • Yoko Yanagisawa
    • Rachel S. Midgley
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 7, P: 556-557

  • This Review article outlines the evolution of non-surgical treatment for colorectal cancer, in particular chemotherapy, its integration with radiotherapy, and the evolving use of biologic therapies. The authors also discuss new advances in patient selection for specific anti-cancer agents and regimens.

    • Rachel S Midgley
    • Yoko Yanagisawa
    • David J Kerr
    Reviews
    Nature Clinical Practice Gastroenterology & Hepatology
    Volume: 6, P: 108-120